BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Skin cancer AND PTPRT, KIAA0283, 11122, ENSG00000196090, O14522, RPTPrho, RP5-1121H13_2 AND Treatment
22005 results:

  • 1. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
    Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
    Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Subminute thermal damage to cell types present in the skin.
    Doppegieter M; van Leeuwen TG; van Weert A; Aalders MCG; Bakker ENTP
    Int J Hyperthermia; 2024; 41(1):2354435. PubMed ID: 38754976
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Clinical versus Histological Assessment of Basal Cell Carcinoma Subtype and Thickness of Tumours Selected for Photodynamic Therapy.
    Mørk E; Mjønes P; Foss OA; Mørk C; Bachmann IM; Kroon S; Dotterud LK; Helsing P; Vatne Ø; Christensen E
    Acta Derm Venereol; 2024 May; 104():adv18308. PubMed ID: 38751175
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Erythema dyschromicum perstans-like eruptions induced by epidermal growth factor receptor inhibitors in patients with lung cancer.
    Bang AS; Said JT; Hirner J; Rana J; Pugliese S; Wang JY; Zaba L; Zhao L; Doan L; Smith J; Kwong BY
    Support Care Cancer; 2024 May; 32(6):354. PubMed ID: 38750379
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Prospective phase II trial of preoperative hypofractionated proton therapy for extremity and truncal soft tissue sarcoma: the PRONTO study rationale and design.
    Gogineni E; Chen H; Hu C; Boudadi K; Engle J; Levine A; Deville C
    Radiat Oncol; 2024 May; 19(1):56. PubMed ID: 38745333
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Hospitalization and mortality in Asian autoimmune bullous dermatosis patients: A 17-year retrospective study.
    Amonchaisakda N; Rujitharanawong C; Tuchinda P; Kulthanan K; Chularojanamontri L
    Exp Dermatol; 2024 May; 33(5):e15095. PubMed ID: 38742822
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [Predicting the effectiveness of organ-preserving treatment of choroidal melanoma using optical coherence tomography data].
    Stoyukhina AS
    Vestn Oftalmol; 2024; 140(2. Vyp. 2):16-20. PubMed ID: 38739126
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. A dosiomics model for prediction of radiation-induced acute skin toxicity in breast cancer patients: machine learning-based study for a closed bore linac.
    Saadatmand P; Mahdavi SR; Nikoofar A; Jazaeri SZ; Ramandi FL; Esmaili G; Vejdani S
    Eur J Med Res; 2024 May; 29(1):282. PubMed ID: 38735974
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. In Vitro and In Vivo Studies of Melanoma Cell Migration by Antagonistic Mimetics of Adhesion Molecule L1CAM.
    Pompili SVB; Fanzini S; Schachner M; Chen S
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732030
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Glycyrrhizic acid inhibits DNA damage repair and enhances cisplatin-induced apoptosis of melanoma cells.
    Bian F; Niu FH; Qu PY; Gong F; Yan JZ
    Chem Biol Drug Des; 2024 May; 103(5):e14536. PubMed ID: 38725079
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Monitoring Adolescent and Young Adult Patients With cancer via a Smart T-Shirt: Prospective, Single-Cohort, Mixed Methods Feasibility Study (OncoSmartShirt Study).
    Steen-Olsen EB; Pappot H; Hjerming M; Hanghoej S; Holländer-Mieritz C
    JMIR Mhealth Uhealth; 2024 May; 12():e50620. PubMed ID: 38717366
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
    Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
    Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
    Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
    Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Beyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma skin cancers.
    Ravipati A; Pradeep T; Nouri K
    J Drugs Dermatol; 2024 May; 23(5):301-305. PubMed ID: 38709693
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Clinical characteristics and research progress of ocular Merkel cell carcinoma].
    Zhang S; Jiang LB
    Zhonghua Yan Ke Za Zhi; 2024 May; 60(5):467-471. PubMed ID: 38706087
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment.
    Feldman SR; Guerin A; Gauthier-Loiselle M; Claxton AJ; Hazra NC; Meng Y; Gallant K; Balu S
    J Dermatolog Treat; 2024 Dec; 35(1):2345739. PubMed ID: 38705585
    [No Abstract]    [Full Text] [Related]  

  • 17. Incidence Rates and Outcomes of Nodular and Superficial Spreading Melanoma along the Rural-Urban Continuum in Kentucky and Their Relationship to Provider Care Access.
    McElroy D; Towery M; Molina-Lopez S; Eastham R; Alexander SG; Mountjoy NJ
    South Med J; 2024 May; 117(5):235-240. PubMed ID: 38701843
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Causal association between lipid-lowering drugs and cancers: A drug target Mendelian randomization study.
    Ding W; Chen L; Xia J; Pei B; Song B; Li X
    Medicine (Baltimore); 2024 May; 103(18):e38010. PubMed ID: 38701318
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Decoding the molecular landscape: A novel prognostic signature for uveal melanoma unveiled through programmed cell death-associated genes.
    Liu Z; Yu L; Lai J; Zhang R
    Medicine (Baltimore); 2024 May; 103(18):e38021. PubMed ID: 38701273
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
    Klabusay M; Bábková B
    Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1101.